The future of polycystic kidney disease research-as seen by the 12 kaplan awardees

Journal of the American Society of Nephrology

Volumn 26, Issue 9, 2015, Pages 2081-2095

  Antignac, Corinne ^a,b   Calvet, James P ^c   Germino, Gregory G ^d   Grantham, Jared J ^c   Guay Woodford, Lisa M ^e   Harris, Peter C ^f   Hildebrandt, Friedhelm ^g   Peters, Dorien J M ^h   Somlo, Stefan ⁱ   Torres, Vicente E ^f   Walz, Gerd ^j   Zhou, Jing ^g   Yu, Alan S L ^c  

^a INSERM US24 CNRS UMS3633   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f MAYO CLINIC   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF FREIBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

POLYCYSTIN; IFT139 PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MICROTUBULE ASSOCIATED PROTEIN; MULTIPROTEIN COMPLEX; POLYCYSTIC KIDNEY DISEASE 1 PROTEIN; POLYCYSTIC KIDNEY DISEASE 2 PROTEIN; TARGET OF RAPAMYCIN KINASE;

ALLELE; AUTOSOMAL DOMINANT INHERITANCE; AWARDS AND PRIZES; CONFERENCE PAPER; DISEASE SEVERITY; DNA DAMAGE; EUKARYOTIC FLAGELLUM; GENOTYPE; GERMLINE MUTATION; HOMOZYGOTE; HUMAN; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE EPITHELIUM; MODIFIER GENE; MOLECULAR MECHANICS; MOUSE MODEL; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SCIENTIST; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TISSUE INJURY; TISSUE REGENERATION; ANIMAL; GENETICS; KIDNEY TUBULE; MEDICAL RESEARCH; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENAL INSUFFICIENCY; TRENDS;

ANIMALS; BIOMEDICAL RESEARCH; CILIA; GENES, MODIFIER; HUMANS; KIDNEY TUBULES; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR TARGETED THERAPY; MULTIPROTEIN COMPLEXES; PHENOTYPE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENAL INSUFFICIENCY; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRPP CATION CHANNELS;

EID: 84940734635     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014121192     Document Type: Conference Paper

References (111)

1. Cornec-Le Gall E, Audrézet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, Charasse C, Whebe B, Renaudineau E, Jousset P, Guillodo MP, Grall-Jezequel A, Saliou P, Férec C, Le Meur Y: Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24: 1006-1013, 2013
2. Islam MR, Jimenez T, Pelham C, Rodova M, Puri S, Magenheimer BS, Maser RL, Widmann C, Calvet JP:MAP/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein. J Biol Chem 285: 38818-38831, 2010
3. Rossetti S, Kubly VJ, ConsugarMB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van't Hoff WG, Niaudet P, Torres VE, Harris PC: Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 75: 848-855, 2009
4. Vujic M, Heyer CM, Ars E, Hopp K, Markoff A, Orndal C, Rudenhed B, Nasr SH, Torres VE, Torra R, Bogdanova N, Harris PC: Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. J Am Soc Nephrol 21: 1097-1102, 2010
5. Bergmann C, von Bothmer J, Ortiz Brüchle N, Venghaus A, Frank V, Fehrenbach H, Hampel T, Pape L, Buske A, Jonsson J, Sarioglu N, Santos A, Ferreira JC, Becker JU, Cremer R, Hoefele J, Benz MR, Weber LT, Buettner R, Zerres K: Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. J Am Soc Nephrol 22: 2047-2056, 2011
6. Zerres K, Rudnik-Schöneborn S, Deget F: Childhood onset autosomal dominant polycystic kidney disease in sibs: clinical picture and recurrence risk. German Working Group on Paediatric Nephrology (Arbeitsgemeinschaft für Pdiatrische Nephrologie. J Med Genet 30: 583-588, 1993
7. Hopp K, Ward CJ, Hommerding CJ, Nasr SH, TuanHF, Gainullin VG, Rossetti S, Torres VE, Harris PC: Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest 122: 4257-4273, 2012
8. Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE: Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol 26: 39-47, 2015
9. Harris PC, Hopp K: The mutation, a key determinant of phenotype in ADPKD. J Am Soc Nephrol 24: 868-870, 2013
10. Connor A, Lunt PW, Dolling C, Patel Y, Meredith AL, Gardner A, Hamilton NK, Dudley CR: Mosaicism in autosomal dominant polycystic kidney disease revealed by genetic testing to enable living related renal transplantation.AmJ Transplant 8: 232-237, 2008
11. Consugar MB, Wong WC, Lundquist PA, Rossetti S, Kubly VJ, Walker DL, Rangel LJ, Aspinwall R, Niaudet WP, Ozen S, David A, Velinov M, Bergstralh EJ, Bae KT, Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Sampson JR, Dawson BD, Harris PC; CRISP Consortium: Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int 74: 1468-1479, 2008
12. Reiterová J, Stekrová J, Merta M, Kotlas J, Eliáková V, Lnenicka P, Korabecná M, Kohoutová M, Tesar V: Autosomal dominant polycystic kidney disease in a family with mosaicism and hypomorphic allele. BMC Nephrol 14: 59, 2013
13. Wang E, Hsieh-Li HM, Chiou YY, Chien YL, Ho HH, Chin HJ, Wang CK, Liang SC, Jiang ST: Progressive renal distortion by multiple cysts in transgenic mice expressing artificial microRNAs against Pkd1. J Pathol 222: 238-248, 2010
14. Zode GS, KuehnMH, Nishimura DY, Searby CC, Mohan K, Grozdanic SD, Bugge K, Anderson MG, Clark AF, Stone EM, Sheffield VC: Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma. J Clin Invest 121: 3542-3553, 2011
15. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, BranstromAA,ColacinoJM,Babiak J, JuWD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL: PTC124 targets genetic disorders caused by nonsense mutations. Nature 447: 87-91, 2007
16. Ong T, Ramsey BW: Modifying disease in cystic fibrosis: current and future therapies on the horizon. Curr Opin Pulm Med 19: 645-651, 2013
17. Qian F, Watnick TJ, Onuchic LF, Germino GG: The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 87: 979-987, 1996
18. Watnick TJ, Torres VE, Gandolph MA, Qian F, Onuchic LF, Klinger KW, Landes G, Germino GG: Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease. Mol Cell 2: 247-251, 1998
19. Pei Y, Watnick T, He N, Wang K, Liang Y, Parfrey P, Germino G, St George-Hyslop P: Somatic PKD2 mutations in individual kidney and liver cysts support a "two-hit" model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. J AmSoc Nephrol 10: 1524-1529, 1999
20. Wu G, D'Agati V, Cai Y, Markowitz G, Park JH, Reynolds DM, Maeda Y, Le TC, Hou H Jr, Kucherlapati R, Edelmann W, Somlo S: Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93: 177-188, 1998
21. Piontek KB, Huso DL, Grinberg A, Liu L, Bedja D, Zhao H, Gabrielson K, Qian F, Mei C, Westphal H, Germino GG: A functional floxed allele of Pkd1 that can be conditionally inactivated in vivo. J Am Soc Nephrol 15: 3035-3043, 2004
22. Yu S, Hackmann K, Gao J, He X, Piontek K, García-González MA, Menezes LF, Xu H, GerminoGG, Zuo J,Qian F: Essential role of cleavage ofPolycystin-1 atGprotein-coupled receptor proteolytic site for kidney tubular structure. Proc Natl Acad Sci U S A 104: 18688-18693, 2007
23. Piontek K, Menezes LF, Garcia-Gonzalez MA, Huso DL, Germino GG: A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med 13: 1490-1495, 2007
24. Magenheimer BS, St John PL, Isom KS, Abrahamson DR, De Lisle RC, Wallace DP, Maser RL, Grantham JJ, Calvet JP: Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator/Na+,K+,2Cl- Co-transporter-dependent cystic dilation. J Am Soc Nephrol 17: 3424-3437, 2006
25. Menezes LF, Zhou F, Patterson AD, Piontek KB, Krausz KW, Gonzalez FJ, Germino GG: Network analysis of a Pkd1-mouse model of autosomal dominant polycystic kidney disease identifies HNF4a as a disease modifier. PLoS Genet 8: e1003053, 2012
26. Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ, Leonhard WN, van de Wal A, Ward CJ, Verbeek S, DeruiterMC, Breuning MH, de Heer E, Peters DJ: Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum Mol Genet 13: 3069-3077, 2004
27. Lantinga-van Leeuwen IS, Leonhard WN, van der Wal A, Breuning MH, de Heer E, Peters DJ: Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice. Hum Mol Genet 16: 3188-3196, 2007
28. Grantham JJ, Cook LT, Wetzel LH, Cadnapaphornchai MA, Bae KT: Evidence of extraordinary growth in the progressive enlargement of renal cysts. Clin J Am Soc Nephrol 5: 889-896, 2010
29. Patel V, Li L, Cobo-Stark P, Shao X, Somlo S, Lin F, Igarashi P: Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia. Hum Mol Genet 17: 1578-1590, 2008
30. Happé H, LeonhardWN, van derWal A, van de Water B, Lantinga-van Leeuwen IS, Breuning MH, de Heer E, Peters DJ: Toxic tubular injury in kidneys fromPkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways. Hum Mol Genet 18: 2532-2542, 2009
31. Leonhard WN, Zandbergen M, Veraar K, van den Berg S, van der Weerd L, Breuning M, de Heer E, Peters DJ: Scattered deletion of Pkd1 in mouse kidneys causes a cystic snowball effect and recapitulates human polycystic kidney disease. J Am Soc Nephrol : 2014 (in press)
32. Wilson PD, Du J, Norman JT: Autocrine, endocrine and paracrine regulation of growth abnormalities in autosomal dominant polycystic kidney disease. Eur J Cell Biol 61: 131-138, 1993
33. Mrug M, Li R, Cui X, Schoeb TR, Churchill GA, Guay-Woodford LM: Kinesin family member 12 is a candidate polycystic kidney disease modifier in the cpk mouse. J Am Soc Nephrol 16: 905-916, 2005
34. Boddu R, YangC,O'ConnorAK,Hendrickson RC, Boone B, Cui X, Garcia-Gonzalez M, Igarashi P, Onuchic LF, Germino GG, Guay-Woodford LM: Intragenic motifs regulate the transcriptional complexity of Pkhd1/PKHD1. J MolMed (Berl) 92(10): 1045-1056, 2014
35. Rossetti S, Harris PC: Genotype-phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease. J Am Soc Nephrol 18: 1374-1380, 2007
36. Hou X, Mrug M, Yoder BK, Lefkowitz EJ, Kremmidiotis G, D'Eustachio P, Beier DR, Guay-Woodford LM: Cystin, a novel ciliaassociated protein, is disrupted in the cpk mouse model of polycystic kidney disease. J Clin Invest 109: 533-540, 2002
37. Garcia-Gonzalez MA, Menezes LF, Piontek KB, Kaimori J, Huso DL,Watnick T, Onuchic LF, Guay-Woodford LM, Germino GG: Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway. Hum Mol Genet 16: 1940-1950, 2007
38. Lambie L, Amin R, Essop F, Krause A, Cnaan A, Guay-Woodford L: Clinical and genetic characterization of a founder PKHD1 mutation in Afrikaners with ARPKD. Pediatr Nephrol 30: 273-279, 2015
39. Logan RW, Robledo RF, Recla JM, Philip VM, Bubier JA, Jay JJ, Harwood C, Wilcox T, Gatti DM, Bult CJ, Churchill GA, Chesler EJ: High-precision genetic mapping of behavioral traits in the diversity outbred mouse population. Genes Brain Behav 12: 424-437, 2013
40. Harris PC, Torres VE: Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. JClin Invest 124: 2315-2324, 2014
41. Torres VE, Harris PC: Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.JAmSocNephrol 25: 18-32, 2014
42. LowranceWT, Ordoñez J,Udaltsova N,Russo P,GoAS:CKDand the risk of incident cancer. J Am Soc Nephrol 25: 2327-2334, 2014
43. Keith DS, Torres VE, King BF, Zincki H, Farrow GM: Renal cell carcinoma in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 4: 1661-1669, 1994
44. Hajj P, Ferlicot S, Massoud W, Awad A, Hammoudi Y, Charpentier B, Durrbach A, Droupy S, Benot G: Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure. Urology 74: 631-634, 2009
45. Jilg CA, Drendel V, Bacher J, Pisarski P, Neeff H,DrognitzO, SchwardtM,Glsker S, Malinoc A, Erlic Z, Nunez M, Weber A, Azurmendi P, Schultze-Seemann W, Werner M, Neumann HP: Autosomal dominant polycystic kidney disease: prevalence of renal neoplasias in surgical kidney specimens. Nephron Clin Pract 123: 13-21, 2013
46. Wetmore JB, Calvet JP, Yu AS, Lynch CF, Wang CJ, Kasiske BL, Engels EA: Polycystic kidney disease and cancer after renal transplantation. J Am Soc Nephrol 25: 2335-2341, 2014
47. Ward CJ, Wu Y, Johnson RA, Woollard JR, Bergstralh EJ, Cicek MS, Bakeberg J, Rossetti S, Heyer CM, Petersen GM, Lindor NM, Thibodeau SN, Harris PC, Torres VE, Hogan MC, Boardman LA: Germline PKHD1 mutations are protective against colorectal cancer. Hum Genet 129: 345-349, 2011
48. Nagao S, Nishii K, Yoshihara D, Kurahashi H, Nagaoka K, Yamashita T, Takahashi H, Yamaguchi T,Calvet JP,WallaceDP: Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat. Kidney Int 73: 269-277, 2008
49. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP: Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279: 40419-40430, 2004
50. LiuH, Radisky DC, YangD, Xu R, Radisky ES, Bissell MJ, Bishop JM: MYC suppresses cancer metastasis by direct transcriptional silencing of av and b3 integrin subunits. Nat Cell Biol 14: 567-574, 2012
51. Xu L, Stevens J, Hilton MB, Seaman S, Conrads TP, Veenstra TD, Logsdon D, Morris H, Swing DA, Patel NL, Kalen J, Haines DC, Zudaire E, St Croix B: COX-2 Inhibition Potentiates Antiangiogenic Cancer Therapy and Prevents Metastasis in Preclinical Models. Sci Transl Med 6: 242ra284, 2014
52. Gallagher AR, Germino GG, Somlo S: Molecular advances in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 17: 118-130, 2010
53. Hildebrandt F, Benzing T, Katsanis N: Ciliopathies. N Engl J Med 364: 1533-1543, 2011
54. Pazour GJ, San Agustin JT, Follit JA, Rosenbaum JL, Witman GB: Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpkmice with polycystic kidney disease. Curr Biol 12: R378-R380, 2002
55. Yoder BK, Hou X, Guay-Woodford LM: The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia.JAmSocNephrol 13: 2508-2516, 2002
56. Lin F, Hiesberger T, Cordes K, Sinclair AM, Goldstein LS, Somlo S, Igarashi P: Kidneyspecific inactivation of the KIF3A subunit of kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease. Proc Natl Acad Sci U S A 100: 5286-5291, 2003
57. Shibazaki S, Yu Z,Nishio S, Tian X, Thomson RB, Mitobe M, Louvi A, Velazquez H, Ishibe S, Cantley LG, Igarashi P, Somlo S: Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet 17: 1505-1516, 2008
58. Ma M, Tian X, Igarashi P, Pazour GJ, Somlo S: Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease. Nat Genet 45: 1004-1012, 2013
59. Zhou J: Polycystins and primary cilia: primers for cell cycle progression. Annu Rev Physiol 71: 83-113, 2009
60. Delmas P, Nomura H, Li X, Lakkis M, Luo Y, Segal Y, Fernández-Fernández JM, Harris P, Frischauf AM, Brown DA, Zhou J: Constitutive activation of G-proteins by polycystin-1 is antagonized by polycystin-2. J Biol Chem 277: 11276-11283, 2002
61. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, Elia AE, Lu W, Brown EM, Quinn SJ, Ingber DE, Zhou J: Polycystins 1 and 2 mediate mechanosensation in the primary ciliumof kidney cells. NatGenet 33: 129-137, 2003
62. Jin X, Mohieldin AM, Muntean BS, Green JA, Shah JV, Mykytyn K,Nauli SM: Cilioplasm is a cellular compartment for calcium signaling in response to mechanical and chemical stimuli. Cell Mol Life Sci 71: 2165-2178, 2014
63. DellingM, DeCaen PG, Doerner JF, Febvay S, Clapham DE: Primary cilia are specialized calcium signalling organelles. Nature 504: 311-314, 2013
64. Wang S, Zhang J,Nauli SM, Li X, Starremans PG, Luo Y, Roberts KA, Zhou J: Fibrocystin/ polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia.Mol Cell Biol 27: 3241-3252, 2007
65. Sohara E, Luo Y, Zhang J, Manning DK, Beier DR, Zhou J: Nek8 regulates the expression and localization of polycystin-1 and polycystin-2. J Am Soc Nephrol 19: 469-476, 2008
66. Su X, Driscoll K, Yao G, Raed A, Wu M, Beales PL, Zhou J: Bardet-Biedl syndrome proteins 1 and 3 regulate the ciliary trafficking of polycystic kidney disease 1 protein. Hum Mol Genet 23: 5441-5451, 2014
67. Yao G, Su X, Nguyen V, Roberts K, Li X, Takakura A, Plomann M, Zhou J: Polycystin-1 regulates actin cytoskeleton organization and directional cell migration through a novel PC1-Pacsin 2-N-Wasp complex. Hum Mol Genet 23: 2769-2779, 2014
68. Karner CM, Chirumamilla R, Aoki S, Igarashi P, Wallingford JB, Carroll TJ: Wnt9b signaling regulates planar cell polarity and kidney tubule morphogenesis. Nat Genet 41: 793-799, 2009
69. Chaki M, Airik R, Ghosh AK, Giles RH, Chen R, Slaats GG, Wang H, Hurd TW, Zhou W, Cluckey A, Gee HY, Ramaswami G, Hong CJ, Hamilton BA, Cervenka I,Ganji RS, Bryja V, Arts HH, van Reeuwijk J, Oud MM, Letteboer SJ, Roepman R, Husson H, Ibraghimov-Beskrovnaya O, Yasunaga T, Walz G, Eley L, Sayer JA, Schermer B, Liebau MC, Benzing T, Le Corre S, Drummond I, Janssen S, Allen SJ, Natarajan S, O'Toole JF, Attanasio M, Saunier S, Antignac C, Koenekoop RK, Ren H, Lopez I, Nayir A, Stoetzel C, Dollfus H, Massoudi R, Gleeson JG, Andreoli SP, Doherty DG, Lindstrad A, Golzio C, Katsanis N, Pape L, Abboud EB, Al-Rajhi AA, Lewis RA, Omran H, Lee EY,Wang S, Sekiguchi JM, Saunders R, Johnson CA, Garner E, Vanselow K, Andersen JS, Shlomai J, Nurnberg G, Nurnberg P, Levy S, Smogorzewska A,Otto EA, Hildebrandt F: Exome capture reveals ZNF423 and CEP164mutations, linking renal ciliopathies to DNA damage response signaling. Cell 150: 533-548, 2012
70. SivasubramaniamS, Sun X, Pan YR,Wang S, Lee EY: Cep164 is a mediator protein required for the maintenance of genomic stability through modulation ofMDC1, RPA, and CHK1. Genes Dev 22: 587-600, 2008
71. Mihatsch MJ, Gudat F, Zollinger HU, Heierli C, ThölenH, Reutter FW: Systemic karyomegaly associated with chronic interstitial nephritis. A new disease entity? Clin Nephrol 12: 54-62, 1979
72. Zhou W, Otto EA, Cluckey A, Airik R, Hurd TW, Chaki M, Diaz K, Lach FP, Bennett GR, Gee HY, Ghosh AK, Natarajan S, Thongthip S, Veturi U, Allen SJ, Janssen S, Ramaswami G, Dixon J, Burkhalter F, Spoendlin M, Moch H, Mihatsch MJ, Verine J, Reade R, Soliman H, Godin M, Kiss D, Monga G, Mazzucco G, Amann K, Artunc F, Newland RC,Wiech T, Zschiedrich S,Huber TB, Friedl A, Slaats GG, Joles JA, Goldschmeding R, Washburn J,Giles RH, Levy S,Smogorzewska A, Hildebrandt F: FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet 44: 910-915, 2012
73. BukanovNO,Moreno SE,Natoli TA, Rogers KA, Smith LA, Ledbetter SR, Oumata N, Galons H, Meijer L, Ibraghimov-Beskrovnaya O: CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle 11: 4040-4046, 2012
74. Ichimura K, Kurihara H, Sakai T: Primary cilia disappear in rat podocytes during glomerular development. Cell Tissue Res 341: 197-209, 2010
75. Huynh Cong E, Bizet AA, BoyerO,Woerner S, Gribouval O, Filhol E, Arrondel C, Thomas S, Silbermann F,CanaudG, Hachicha J, BenDhia N, Peraldi MN, Harzallah K, Iftene D, Daniel L, Willems M, Noel LH, Bole-Feysot C, Nitschké P,GublerMC,MolletG, Saunier S, AntignacC: Ahomozygousmissensemutation in theciliary gene TTC21B causes familial FSGS. J AmSoc Nephrol 25: 2435-2443, 2014
76. Davis EE, Zhang Q, Liu Q, Diplas BH, Davey LM, Hartley J, Stoetzel C, Szymanska K, Ramaswami G, Logan CV,Muzny DM, Young AC,WheelerDA,CruzP,MorganM, Lewis LR, Cherukuri P, Maskeri B, Hansen NF, Mullikin JC, Blakesley RW, Bouffard GG, Gyapay G, Rieger S, Tönshoff B, Kern I, Soliman NA, Neuhaus TJ, Swoboda KJ, Kayserili H, Gallagher TE, Lewis RA, Bergmann C, Otto EA, Saunier S, Scambler PJ, Beales PL, Gleeson JG,Maher ER, Attié-Bitach T,Dollfus H, Johnson CA, Green ED, Gibbs RA, Hildebrandt F, Pierce EA, Katsanis N; NISC Comparative Sequencing Program: TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum.NatGenet 43: 189-196, 2011
77. Welsh GI, Saleem MA: The podocyte cytoskeleton-key to a functioning glomerulus in health and disease. Nat Rev Nephrol 8: 14-21, 2012
78. Sussman CR,Ward CJ, Leightner AC, Smith JL, Agarwal R, Harris PC, Torres VE: Phosphodiesterase 1A Modulates Cystogenesis in Zebrafish. J Am Soc Nephrol 25: 2222-2230, 2015
79. Buchholz B, Faria D, Schley G, Schreiber R, Eckardt KU, Kunzelmann K: Anoctamin 1 induces calcium-activated chloride secretion and proliferation of renal cyst-forming epithelial cells. Kidney Int 85: 1058-1067, 2014
80. Ravichandran K, Zafar I, He Z, Doctor RB, Moldovan R, Mullick AE, Edelstein CL: An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2. Hum Mol Genet 23: 4919-4931, 2014
81. Serra AL, PosterD, Kistler AD, Krauer F, Raina S,Young J, RentschKM, Spanaus KS, SennO, Kristanto P, ScheffelH,Weishaupt D, Wüthrich RP: Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363: 820-829, 2010
82. Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, Ondei P, Rubis N, DiadeiO, Gherardi G, Prandini S, Panozo A, Bravo RF, Carminati S, De Leon FR, Gaspari F, Cortinovis M, Motterlini N, Ene-Iordache B, Remuzzi A, Remuzzi G: Sirolimus therapy to halt the progression of ADPKD. J AmSoc Nephrol 21: 1031-1040, 2010
83. WalzG, Budde K,MannaaM, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstdt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU: Everolimus in patients with autosomal dominant polycystic kidney disease.NEngl J Med 363: 830-840, 2010
84. Zhou X, Fan LX, Sweeney WE Jr, Denu JM, Avner ED, Li X: Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. JClin Invest 123: 3084-3098, 2013
85. Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M, Song XW, Xu H, Mari S, Qian F, Pei Y,Musco G, Boletta A: Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 19: 488-493, 2013
86. Sabbatini M, Russo L, Cappellaio F, Troncone G, Bellevicine C, De Falco V, Buonocore P, Riccio E, Bisesti V, Federico S, Pisani A: Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. Am J Physiol Renal Physiol 306: F1243-F1250, 2014
87. Boletta A: Emerging evidence of a link between the polycystins and the mTOR pathways. Pathogenetics 2: 6, 2009
88. Ibraghimov-Beskrovnaya O, Natoli TA: mTOR signaling in polycystic kidney disease. Trends Mol Med 17: 625-633, 2011
89. Boehlke C, Kotsis F, Patel V, Braeg S, Voelker H, Bredt S, Beyer T, Janusch H, Hamann C, Gödel M, Müller K, Herbst M, Hornung M, Doerken M, Köttgen M, Nitschke R, Igarashi P, Walz G, Kuehn EW: Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat Cell Biol 12: 1115-1122, 2010
90. Shillingford JM,Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103: 5466-5471, 2006
91. Dere R,Wilson PD, Sandford RN,Walker CL: Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR. PLoS ONE 5: e9239, 2010
92. Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, Piontek KB,GerminoGG, Pandolfi PP, Boletta A: Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol 29: 2359-2371, 2009
93. Qin S, Taglienti M, Nauli SM, Contrino L, Takakura A, Zhou J, Kreidberg JA: Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease. J Clin Invest 120: 3617-3628, 2010
94. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycinmarkedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16: 46-51, 2005
95. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP: Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21: 598-604, 2006
96. Shillingford JM, Piontek KB, Germino GG, Weimbs T: Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J AmSocNephrol 21: 489-497, 2010
97. Zafar I, Ravichandran K, Belibi FA, Doctor RB, Edelstein CL: Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int 78: 754-761, 2010
98. Shillingford JM, Leamon CP, Vlahov IR, Weimbs T: Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol 23: 1674-1681, 2012
99. Stayner C, Shields J, Slobbe L, Shillingford JM, Weimbs T, Eccles MR: Rapamycinmediated suppression of renal cyst expansion in del34 Pkd1-/-mutantmouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus. Nephrology (Carlton) 17: 739-747, 2012
100. Novalic Z, van der Wal AM, Leonhard WN, Koehl G, Breuning MH, Geissler EK, de Heer E, Peters DJ: Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease.JAmSocNephrol 23: 842-853, 2012
101. Soliman A, Zamil S, Lotfy A, Ismail E: Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment. Transplant Proc 44: 2936-2939, 2012
102. Jardine MJ, Liyanage T, Buxton E, Perkovic V: mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open. Nephrol Dial Transplant 28: 242-244, 2013
103. Braun WE, Schold JD, Stephany BR, Spirko RA, Herts BR: Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study. Clin J AmSoc Nephrol 9: 881-888, 2014
104. Grantham JJ: Polycystic kidney disease: neoplasia in disguise. Am J Kidney Dis 15: 110-116, 1990
105. Grantham JJ, Geiser JL, Evan AP: Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Int 31: 1145-1152, 1987
106. Grantham JJ, Mulamalla S, Swenson-Fields KI: Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 7: 556-566, 2011
107. Chevalier RL, Forbes MS: Generation and evolution of atubular glomeruli in the progression of renal disorders. J Am Soc Nephrol 19: 197-206, 2008
108. Forbes MS, Thornhill BA, Chevalier RL: Proximal tubular injury and rapid formation of atubular glomeruli in mice with unilateral ureteral obstruction: a new look at an old model. Am J Physiol Renal Physiol 301: F110-F117, 2011
109. Galarreta CI, Grantham JJ, Forbes MS, Maser RL, Wallace DP, Chevalier RL: Tubular obstruction leads to progressive proximal tubular injury and atubular glomeruli in polycystic kidney disease. Am J Pathol 184: 1957-1966, 2014
110. Fonseca JM, Bastos AP,AmaralAG, SousaMF, Souza LE, Malheiros DM, Piontek K, Irigoyen MC,Watnick TJ,Onuchic LF: Renal cystgrowth is the main determinant for hypertension and concentrating deficit in Pkd1-deficient mice. Kidney Int 85: 1137-1150, 2014
111. WangX,WuY,Ward CJ,Harris PC, TorresVE: Vasopressin directly regulates cyst growth in polycystic kidney disease. J AmSoc Nephrol 19: 102-108, 2008